BioTech IP Review

Assignee: CorMedix Inc.
Patent Number: 11,738,120
Filed: May 1, 2023 (notice of allowance; application arguably filed earlier)
Issued: August 29, 2023
Expiration: April 15, 2042

What the Patent Covers

This patent protects the unique formulation of DefenCath®, a catheter lock solution composed of antimicrobial and anticoagulant components designed to:

• Prevent catheter‑related bloodstream infections (CRBSIs) in patients with central venous catheters.
• Maintain blood flow in the catheter by reducing clotting alongside infection prevention.
• The invention includes novel compositions and methods for instilling and using the solution in clinical settings.

The solution includes taurolidine (an antimicrobial) and heparin (an anticoagulant), which together address both infection and blood flow issues in hemodialysis and related catheter uses.

Why This Patent Is Important

• Core IP for revenue: DefenCath is CorMedix’s lead commercial product; this patent underpins its exclusivity and differentiates it from competitor lock solutions. The composition claim is central to protecting sales.
• Long protection window: Protection through 2042 gives CorMedix extended market exclusivity, important as DefenCath adoption expands across inpatient and outpatient settings in 2025.
• Regulatory leverage: CorMedix also can seek listing of this patent in the FDA’s Orange Book, strengthening its position against generics and reinforcing statutory exclusivity tied to DefenCath’s designation as a Qualified Infectious Disease Product (QIDP) and New Chemical Entity (NCE).
• Commercial impact: With increasing use in hemodialysis and potential label expansion into broader catheter uses, the DefenCath patent continues to be the biggest patent asset influencing CorMedix’s business value and earnings trajectory.